# A Study of LY4268989 (MORF-057) in Healthy Participants

> **NCT06964776** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 144 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** LY4268989
- **DRUG:** Placebo
- **DRUG:** Midazolam
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT06964776
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-05-01
- **Primary completion:** 2026-02-17
- **Final completion:** 2026-02-17
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06964776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06964776, "A Study of LY4268989 (MORF-057) in Healthy Participants". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06964776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*